Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeOnc Technologies HoldingsNTHI +1.74%7 EV-to-EBITDA is -2.57 as of Aug. 07, 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 409 Biotechnology companies, NeOnc Technologies Holdings ranks worse than 244498.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NeOnc Technologies Holdings's enterprise value is $90.97 Mil.
NeOnc Technologies Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-35.39 Mil. Therefore, NeOnc Technologies Holdings's EV-to-EBITDA for today is -2.57.
The historical rank and industry rank for NeOnc Technologies Holdings's EV-to-EBITDA or its related term are showing as below:
NTHI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7 Med: -2.98 Max: -1.33
Current: -2.57
During the past 5 years, the highest EV-to-EBITDA of NeOnc Technologies Holdings was -1.33. The lowest was -33.70. And the median was -2.98.
NTHI's EV-to-EBITDA is ranked worse than 100% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs NTHI: -2.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NeOnc Technologies Holdings's PE Ratio (TTM) for today is calculated as:
NeOnc Technologies Holdings's share price for today is $3.50.
NeOnc Technologies Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NeOnc Technologies Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeOnc Technologies Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NeOnc Technologies Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NeOnc Technologies Holdings's EV-to-EBITDA falls into.
NeOnc Technologies Holdings's current Enterprise Value is $90.97 Mil.
NeOnc Technologies Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeOnc Technologies Holdings (NTHI) has a EV-to-EBITDA of -2.57 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NeOnc Technologies Holdings. According to the industry distribution chart, NeOnc Technologies Holdings ranks #999999 out of 409 companies in the Biotechnology industry.
Is NeOnc Technologies Holdings' EV-to-EBITDA too high?
NeOnc Technologies Holdings' current EV-to-EBITDA is -2.57. Based on the distribution chart, NeOnc Technologies Holdings ranks #999999 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' EV-to-EBITDA compare to BMEA and PTHS?
According to the Biotechnology industry distribution chart, NeOnc Technologies Holdings ranks #999999 out of 409 companies for EV-to-EBITDA. This places NeOnc Technologies Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NeOnc Technologies Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeOnc Technologies Holdings's current EV-to-EBITDA is -2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current EV-to-EBITDA of -2.57. The current EV-to-EBITDA is -2.57. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current EV-to-EBITDA is -2.57 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score
Get the complete analysis for NTHI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTHI has been successfully added to your 
